Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of CK2 in human 786-0 cells assessed as decrease in alpha-catenin phosphorylation at Ser641 assuming basal level of non-responsive P-alpha-catenin of 50% of DMSO control after 24 hrs by Western blot analysis
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of recombinant human CK2 assessed as residual activity at 1 uM in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control
Assay data:2 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of recombinant human CK2 assessed as residual activity at 10 uM in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control
Assay data:1 Tested
Inhibition of human CK2 at 10 uM
Inhibition of human recombinant CK2 expressed in Escherichia coli using RRRADDSDDDDD as substrate after 10 mins in presence of [gamma-32P]ATP
Assay data:9 Active, 6 Activity ≤ 1 µM, 9 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of human CK2 at 1 uM relative to control
Inhibition of recombinant full length human CK2 at 10 uM relative to control
Inhibition of recombinant human CK2 in presence of [gamma-33ATP] by radiometric scintillation counting analysis
Inhibition of recombinant full length human CK2 expressed in insect Sf21 cells at 1 uM using CK2 substrate peptide as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control
Inhibition of CK2 (unknown origin) at 1 uM relative to control
Inhibition of CK2 in human 786-0 cells assessed as decrease in Akt1 phosphorylation at Ser129 after 24 hrs by Western blot analysis
Assay data:3 Active, 2 Activity ≤ 1 µM, 4 Tested
Inhibition of CK2 in human 786-0 cells assessed as decrease in alpha-catenin phosphorylation at Ser641 after 24 hrs by Western blot analysis
Assay data:3 Active, 1 Activity ≤ 1 µM, 3 Tested
Inhibition of CK2 in human 786-0 cells assessed as decrease in p21 phosphorylation at Thr145 after 24 hrs by Western blot analysis
Inhibition of CK2 in human 786-0 cells assessed as reduction in STAT3 phosphorylation at Y705 after 24 hrs by Western blot analysis
Assay data:2 Active, 2 Tested
Inhibition of CK2 (unknown origin) using recombinant full length p53 as substrate at 20 uM incubated for 30 mins by spectrometry relative to control
Assay data:18 Tested
SummaryRelated BioAssays by Target
Inhibition of CK2 (unknown origin) using recombinant full length p53 as substrate incubated for 30 mins by spectrometry
Assay data:5 Active, 2 Activity ≤ 1 µM, 18 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Inhibition of CK2 (unknown origin)
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Inhibition of human CK2 using HRRRDDD-SDDD-NH2 as substrate after 30 mins by ADP-Glo reagent based luminescence assay
Inhibition of casein kinase 2 in human liver
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on